Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HK1 | P19367 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841914 | 0.79 | MAPT (0.48) | HTR5AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL8558277 | 0.79 | ALOX15 (0.50) | HTR5AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL310398 | 0.77 | HTR5A (0.57) | HTR5AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL30668800 | 0.76 | — | — | |
| SCHEMBL2041999 | 0.76 | — | — | |
| SCHEMBL1828551 | 0.76 | — | — | |
| SCHEMBL11441092 | 0.76 | HTR5A (0.55) | HTR5AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL5740686 | 0.74 | ALOX15 (0.57) | HTR5AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL45104 | 0.74 | HTR5A (0.53) | HTR5AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL10061748 | 0.74 | HTR5A (0.53) | HTR5AMAPTNPC1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-20020032262-A1 | 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds | ZHANG JINFANG (US) | 2002-03-14 | — | — | US | claimed |
| US-20260008777-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-08 | — | — | US | disclosed |
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| CN-116568675-A | Cyclic isothiourea derivatives as CXCR4 modulators | 埃尔米乌治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-3990436-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| CN-114040911-A | As NAV1.8 inhibitors of 2, 3-dihydroquinazoline compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-5043327-A | Treating mammals with congestive heart failure | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-27 | — | — | US | disclosed |
| CN-1051560-A | Contractile and relaxing force enhancing 3, 5-dihydroimidazo [2, 1-b ] quinazolin-2 (1H) -one derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1991-05-22 | — | — | CN | disclosed |
| EP-0406958-A2 | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-01-09 | — | — | EP | disclosed |
| US-4738964-A | Method of suppressing the immune system comprising administering 5H-thiazolo[2,3-b]quinazoline-3(2H)-one | PENNWALT CORPORATION (US) | 1988-04-19 | — | — | US | disclosed |
| US-4588812-A | Substituted 2,3-dihydro-5H-thiazolo[2,3,-b]quinazoline derivatives | PENNWALT CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| US-4228167-A | Diuretic and vasodilating tricyclic quinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-10-14 | — | — | US | disclosed |
| US-4202974-A | Process for preparing 3,4-dihydro-2(1H)-quinazolinone derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-05-13 | — | — | US | disclosed |
| US-3997564-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1976-12-14 | — | — | US | disclosed |
| US-3856960-A | METHOD OF INHIBITING INFLAMMATION USING 1,4-DISUBSTITUTED-METHYLENEDIOXY-2(1H)-QUINAZOLINONES AND QUINAZOLINTHIONES | SANDOZ AG | 1974-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008777-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPRO, PTPRC, PTPRR | HTR5A 2312/4885MAPT 451/4885NPC1 1427/4885 |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | HTR5A 469/4885MAPT 215/4885NPC1 1212/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | HTR5A 2920/4885MAPT 4710/4885NPC1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.